AtriCure to Present at the Stifel Healthcare Conference
October 20 2017 - 8:00AM
Business Wire
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments for atrial fibrillation (Afib) and left atrial appendage
(LAA) management, today announced that it will present at the
Stifel Healthcare Conference at the Palace Hotel in New York on
Tuesday, November 14, 2017. Management is scheduled to present
at 4:15 p.m. Eastern Time. A live audio webcast of the
presentation may be accessed by visiting the Investors page of
AtriCure’s corporate website at ir.atricure.com. A replay of the
presentation will be available for 90 days following the
presentation.
About AtriCure
AtriCure, Inc. provides innovative technologies for the
treatment of Afib and related conditions. Afib affects more than 33
million people worldwide. Electrophysiologists and cardiothoracic
surgeons around the globe use AtriCure technologies for the
treatment of Afib and reduction of Afib related complications.
AtriCure’s Isolator® Synergy™ Ablation System is the first and only
medical device to receive FDA approval for the treatment of
persistent Afib. AtriCure’s AtriClip Left Atrial Appendage
Exclusion System products are the most widely sold LAA management
devices worldwide, with more than 100,000 implanted to date. For
more information, visit AtriCure.com or follow us on Twitter
@AtriCure.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171020005056/en/
AtriCure, Inc.Andy Wade, 513-755-4564Senior Vice President and
Chief Financial Officerawade@atricure.comorGilmartin GroupLynn
Pieper Lewis, 415-937-5402Investor
Relationslynn@gilmartinir.com
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Mar 2024 to Apr 2024
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Apr 2023 to Apr 2024